High materiality8/10
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
Why it may matterVerify against the original reporting
Analyst upgrade implies meaningful upside guidance for NTLA.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Evercore ISI raises NTLA to Outperform with a $24 target; current price $11.24.
- Evercore ISI upgrades NTLA to Outperform; target $24; price $11.24.
Key facts
- 01
Target: $24
- 02
Posted price: $11.24
- 03
Analyst firm: Evercore ISI
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.